United States: FDA Devices Center Issues Multiple Guidances In The Obama Administration's Final Months

Last Updated: February 27 2017
Article by Michele Buenafe and M. Elizabeth Bierman

A flurry of regulatory activity preceded the transition in administration on January 20.

Anticipating that the new administration would impose a regulatory slowdown, the Food and Drug Administration's (FDA's or the Agency's) Center for Devices and Radiological Health (CDRH) issued more than a dozen draft and final guidances from December to January 19. These guidances address a wide range of topics, including investigational device exemptions, cybersecurity, combination products, postmarket surveillance, and medical product communications. An executive order issued by US President Donald Trump may impact the issuance of final versions of the draft guidances issued during this period as well as new guidances.

For those clients and friends who may not have kept up with CDRH's flurry of activity prior to January 20, this LawFlash provides brief summaries of those draft and final guidance documents issued during this period that have broad applicability. We have not included device-specific guidance documents.

Final Guidances

Public Notification of Emerging Postmarket Medical Device Signals

This final guidance, issued December 14, 2016, establishes a process for issuing notifications to the public on new and evolving benefit-risk information (referred to as "emerging signals") about medical devices. As described in our December 21 LawFlash, this final guidance includes several changes to address concerns that emerging signals notifications would be issued based on unreliable or unconfirmed information.

Postmarket Management of Cybersecurity in Medical Devices

As described in a prior LawFlash, FDA issued this final guidance on December 28, 2016 to advise device manufacturers on the applicability of FDA's medical device correction and removal reporting requirements to devices with known cybersecurity vulnerabilities, and to recommend that manufacturers define and document processes for assessing cybersecurity risks for their devices.

Medical Device Accessories – Describing Accessories and Classification Pathway for New Accessory Types

On December 30, 2016, FDA issued its final guidance for medical device accessories. This guidance defines "accessory," describes FDA's policy on classification of accessories, and encourages manufacturers to use the de novo classification process to request classification of new types of accessories. This final guidance includes changes to address concerns that the proposed guidance could blur the line between device components (which are not subject to direct FDA oversight) and device accessories. In addition, this final guidance reflects the new statutory requirements for accessory classifications that were included in the recently enacted 21st Century Cures Act (Pub. L. 114-255).

Current Good Manufacturing Practice Requirements for Combination Products

This final guidance, issued January 11, 2017, describes and explains FDA's January 22, 2013 final rule on current good manufacturing practice (CGMP) requirements for combination products (21 C.F.R. Part 4). The final rule is intended to clarify which CGMP requirements apply when drugs, devices, and biological products are combined to create combination products, and to streamline the regulatory framework for manufacturers of such products. This guidance provides further information on the purpose and content of specific CGMP requirements included in the final rule, and includes hypothetical scenarios to help explain how to comply with CGMP requirements for specific types of combination products.

Factors to Consider When Making Benefit-Risk Determinations for Medical Device Investigational Device Exemptions

FDA issued this final guidance on January 13, 2017 to clarify for clinical study sponsors and sponsor-investigators what factors FDA considers when assessing the risks and anticipated benefits of investigational device exemption (IDE) applications for clinical studies. This guidance further discusses how risk mitigation measures can help ensure appropriate protections for study subjects. Notably, FDA states that the total product life cycle of the device will be considered, and it expects a greater amount of uncertainty at earlier stages of device development. Additionally, FDA will consider the contextual setting in which the study is being proposed, including the disease or condition being treated or diagnosed, the availability of and risks associated with alternative treatments or diagnostics, and any information regarding the subjects' tolerance for risk and perspective on the benefit.

Emergency Use Authorization of Medical Products and Related Authorities

FDA's Office of Counterterrorism and Emerging Threats prepared this final guidance, which issued January 13, 2017, to explain FDA's procedures for authorizing the emergency use of certain medical products. These procedures are intended to implement certain laws that support national preparedness for public health, military, and domestic emergencies involving chemical, biological, radiological, and nuclear (CBRN) agents, including emerging infectious disease threats such as pandemic influenza. Medical devices that may be required in such situations include in vitro diagnostics and personal protective equipment.

Draft Guidances

How to Prepare a Pre-Request for Designation (Pre-RFD)

This draft guidance, issued January 13, 2017, describes a proposed new process to obtain informal, nonbinding feedback on FDA's determination of whether a product will be considered a combination product or a drug, device, or biological product. FDA states that this draft guidance is intended to make transparent the process that its Office of Combination Products has been following, and is in response to requests from sponsors. Unlike the formal request for designation process, the pre-RFD need not include detailed manufacturing information, supportive data/studies, or an analysis of the classification or primary mode of action. Additionally, there is no user fee for a pre-RFD. Comments on this draft guidance should be submitted by April 13, 2017 in order to be considered before FDA begins work on the final guidance.

Medical Product Communications That Are Consistent with the FDA-Required Labeling – Questions and Answers

FDA announced this draft guidance, which discusses one of the most controversial (and much litigated) areas of FDA regulation, on the last day of the Obama administration, January 19, 2017. This draft guidance, which applies to drugs and biological products as well as devices, describes how FDA evaluates firms' medical product communications that present information not specifically contained in the FDA-required labeling, but that is consistent with such labeling. Additionally, it provides recommendations on how to convey such "consistent" information in a way that is truthful and not misleading. FDA requests that comments on this draft guidance be submitted by April 19, 2017.

Drug and Device Manufacturer Communications with Payors, Formulary Committees, and Similar Entities – Questions and Answers

FDA also issued this draft guidance on January 19, 2017, contemporaneously with the above-referenced guidance on medical product communications. This draft guidance addresses dissemination of information about investigational devices to payors before FDA approval or clearance of such products. It also addresses communications for drugs and biological products, including communications related to healthcare economic information per Section 502(a) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 352(a)), which was recently modified and expanded under the 21st Century Cures Act. This draft guidance is intended to provide further clarity to firms and payors regarding when dissemination of healthcare economic information will not be considered false or misleading. FDA is accepting comments on this draft guidance until April 19, 2017.

This article is provided as a general informational service and it should not be construed as imparting legal advice on any specific matter.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Similar Articles
Relevancy Powered by MondaqAI
McDermott Will & Emery
Akin Gump Strauss Hauer & Feld LLP
In association with
Related Topics
Similar Articles
Relevancy Powered by MondaqAI
McDermott Will & Emery
Akin Gump Strauss Hauer & Feld LLP
Related Articles
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Registration (you must scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions

Mondaq.com (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of www.mondaq.com

To Use Mondaq.com you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.


The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.


Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions